A to Z / Approved medicine
Icatibant
Also known as Firazyr.
Best known for The self-injected rescue for hereditary angioedema
Evidence★★★★★
Safety dataWell characterised
Route subcutaneous injection into the abdomen, self-administered
United StatesFDA approved
AustraliaSchedule 4: prescription only
as at 16 September 2026
What it is and what it does
Icatibant is a ten-amino-acid bradykinin B2 receptor antagonist. It is an approved medicine used to treat acute attacks of hereditary angioedema in adults.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with Enfuvirtide, Teduglutide
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Icatibant. It is not medical advice and not a recommendation to use it.